Hospitals Superbug Crisis: Infections Spread Rapidly
- * NDM-CRE (New Delhi metallo-beta-lactamase-producing carbapenem-resistant Enterobacterales) infections are rapidly increasing in the United States.
- * Resistance genes are located on plasmids, allowing them to easily spread between different bacteria species and hospitals.
- * NDM-CRE can cause pneumonia, bloodstream infections, urinary tract infections, and wound infections.
Deadly Superbug on the Rise: NDM-CRE Infections Increasing in US Hospitals
Here’s a summary of the article, focusing on the key takeaways:
The Problem:
* NDM-CRE (New Delhi metallo-beta-lactamase-producing carbapenem-resistant Enterobacterales) infections are rapidly increasing in the United States. This is a particularly dangerous type of antibiotic-resistant bacteria.
* CRE bacteria are gut bacteria that have become resistant to carbapenem antibiotics, a class of drugs often used as a last resort for serious infections. NDM is a particularly potent enzyme that renders many antibiotics ineffective.
* The rise in NDM-CRE is a meaningful threat because it limits treatment options for serious bacterial infections.
* Mortality rates for CRE infections are high,ranging from 26% to 44% in clinical studies.
Why it’s happening & How it Spreads:
* Resistance genes are located on plasmids, allowing them to easily spread between different bacteria species and hospitals.
* Many clinical labs lack the ability to identify the specific carbapenemase (like NDM) causing the resistance, delaying appropriate treatment.
* Silent carriers can spread the infection if it’s not identified quickly.
What Infections it Causes:
* NDM-CRE can cause pneumonia, bloodstream infections, urinary tract infections, and wound infections.
* High-risk patients include those in intensive care, transplant recipients, and those with long hospital stays.
How Hospitals are responding:
* The CDC’s AR Lab Network can perform testing through public health labs when hospital labs can’t.
* labs use phenotypic and molecular tests to identify the carbapenemase.
* Rapid testing is crucial for isolating patients and controlling outbreaks.
Treatment Options:
* Few drugs remain effective against NDM-CRE.
* Current recommendations include cefiderocol or a combination of aztreonam with ceftazidime avibactam.
In essence, the article highlights a growing public health concern: the increasing prevalence of a highly drug-resistant superbug that poses a serious threat to patient safety, particularly in hospital settings. The need for rapid and accurate diagnostic testing is emphasized as a critical step in combating this threat.